Maintenance treatment for TP53-wildtype endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests navtemadlin as a maintenance (ongoing) treatment to help prevent endometrial cancer from coming back after chemotherapy works. It is mainly for people whose cancer has certain genetic features (TP53 “wildtype”) and who had a strong response to first-line taxane–platinum chemo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can move and care for yourself fairly well (ECOG 0–1).
- Your endometrial cancer is confirmed as TP53 wildtype (TP53WT).
- If your cancer is advanced or has returned, you finished up to 6 cycles of taxane–platinum chemo and had a complete or partial response.
- Your blood counts and liver and kidney tests are strong enough within the last 2 weeks.
- You have not had certain treatments in the last 28 days (immune therapy, cytokine therapy, or other investigational drugs).
- You do not have certain safety issues (examples: heart rhythm QTc prolongation Grade 2+, history of major bleeding in the last 24 weeks, or recent intracranial bleeding).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking two oral medications (letrozole and abemaciclib) after standard chemotherapy can help keep advanced or recurrent endometrial cancer from coming back. It is for people whose cancer is estrogen receptor-positive and has certain favorable genetic features.
This study tests a new drug (PF-08634404) combined with chemotherapy for women with advanced or recurrent endometrial cancer that is MMR-proficient. The goal is to see if this combination works better than standard care.
This trial tests a combination of two investigational drugs—anlotinib (a capsule that blocks blood supply to tumors) and TQB2450 (an immunotherapy that helps your immune system attack cancer cells)—for people with recurrent or metastatic endometrial cancer that has not responded to previous platinum-based chemotherapy. The goal is to see if this combo can shrink tumors or slow their growth.
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
This trial tests a combination of two targeted pills (sapanisertib and serabelisib) with standard chemo (paclitaxel) for endometrial cancer that has come back or spread. A substudy also looks at combining these drugs with a special diet that lowers insulin levels.
This trial tests a chemotherapy combination (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab, followed by maintenance pembrolizumab either alone or with a PARP inhibitor called nesuparib. It is for women with advanced or recurrent endometrial cancer that is MMR-proficient (a type where the cells have a normal ability to fix DNA).
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.